July 17, 2019 7:39am

It’s in the “machine” – definitely not in the hands of investors

It's a daunting task to understand risk, seeing the unforeseen; on the basis of my own rules of reliability, I set-up my own “warning analysis” which isn’t machine oriented! 

 

A primer for Wednesday; share pricing should show some movement …

 

Sustainability remains a cause for concern

 

Dow futures are UP +0.02% (+6 points), S&P futures are UP +0.03% (+1 points) and NASDAQ futures are UP +0.11% (+9 points)

 

U.S. stock index futures pointed to a slightly higher open;

European stocks were muted over reignited fears over trade;

Asia stocks were mostly lower following overnight developments on the US-China trade front;

 

Data docket: housing starts figures for June are due at 8.30 a.m. ET while EIA crude oil stocks change data is set for release at 10.30 a.m. ET.

 

Henry’omics:

Is the sector about to regain momentum – it’s time in marginal increments!

I care where share pricing is going in the short term; near term – eh, it will go somewhere mostly down and then up to fall again; the real issue is, I don't really care where a stock is going in the long term because the “growing season” is fraught with dry periods and how many of us will be around to see it!

On the geopolitical front, President Trump said the world’s two largest economies have a “long way to go” on trade, and suggested that the U.S. could impose sanctions on an additional $325 billion worth of Chinese goods.

From Tuesday’s evening post, “Expectations are low in share pricing’ it’s all about perception and what risks are under the surface as sentiment sinks as to what might happen as earnings season ramps.”

  • The NASDAQ was down -35.29 or -0.43% to 8222.80;
  • Tuesday the IBB closed down -0.58% while the XBI closed down -0.84%;
  • The close was negative with an A/D Line of 15/27 and 1 flat and 2 acquired;
  • 4 out of the 15 upside had higher than the 3 month average volume;
  • 3 out of the 27 downside had higher than the 3 month average volume;
  • Q3/19 so far: there were 3 positive, 1 holiday and 8 negative closes;

 

Companies in my headlights – It’s your decision; I provide an idea and context:

Oversold at the close:

  • Sage Therapeutics (SAGE -$7.15) – earnings 8/6
  • CRISPER Therapeutics (CRSP -$0.78)
  • Editas Medicine (EDIT -$0.97)

Overbought:

  • ReNeuron (RENE.L +$18.50)

 

 

Opinions expressed are those of the author and are subject to change, and not intended to be a forecast of future events, a guarantee of future results, nor investment advice.

Whether information or intelligence is good, bad or somewhere in between; I put into context what is relevant and useful for investors.  All investments are subject to risks. Investors should consider investment objectives.

Henry McCusker, the editor and publisher of RegMed Investors does not hold or have positions in securities referred to in this publication.